Manski T J, Heffner D K, Glenn G M, Patronas N J, Pikus A T, Katz D, Lebovics R, Sledjeski K, Choyke P L, Zbar B, Linehan W M, Oldfield E H
Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1414, USA.
JAMA. 1997 May 14;277(18):1461-6. doi: 10.1001/jama.277.18.1461.
Isolated reports suggest a possible association of endolymphatic sac tumors (ELSTs), which are extremely rare in the general population, with von Hippel-Lindau disease (VHL). To determine if hearing loss and ELSTs are a component of VHL, we examined prevalence, clinical presentation, and natural history of hearing loss and ELSTs in VHL.
Brain magnetic resonance images (MRIs) from 374 patients screened for VHL were reviewed for evidence of ELSTs. The VHL patients with MRI evidence suggestive of ELSTs or a history of hearing loss, tinnitus, or vertigo underwent additional radiologic and audiologic evaluations. To further assess prevalence of hearing loss and ELST in VHL, the next 66 patients screened in the VHL clinic (49 with proven VHL, 17 at risk for VHL) received MRI and audiologic assessment.
Referral center.
Study subjects comprised 374 persons screened for VHL, 66 consecutive patients with VHL or at risk for VHL, 4 patients with 6 ELSTs, and 13 previously reported patients with VHL and invasive tumors of the temporal bone.
Magnetic resonance image and computed tomographic (CT) scan of the posterior fossa and audiologic assessment.
Any ELST visible on MRI or CT and hearing loss compatible with ELST.
Magnetic resonance imaging revealed evidence of 15 ELSTs in 13 (11%) of 121 patients with VHL, but in none of the 253 patients without evidence of VHL (P<.001). Clinical findings in these 13 patients included hearing loss (13), tinnitus (12), vertigo (8), and facial paresis (1). Mean age at onset of hearing loss was 22 years (range, 12-50 years). Hearing for pure tones was abnormal in all affected ears and in 6 of the 11 additional, allegedly unaffected ears. In 8 patients (62%), hearing loss was the first manifestation of VHL. Presence or absence of hearing loss was associated with duration of symptoms (P<.002) and with tumor size (P<.01). Further, 43 (65%) of the 66 patients from the VHL clinic had pure tone threshold abnormalities, abnormalities that occurred bilaterally in 23 (54%) of the 43 affected subjects; however, evidence is lacking for a definitive association with ELST (3 [6%] of 49 patients with proven VHL had ELST evident on MRI).
Hearing loss and ELSTs are frequently associated with VHL syndrome and should be considered when screening individuals at risk for VHL and when monitoring patients with an established diagnosis of VHL. Many patients with VHL have hearing loss without radiographic evidence of an ELST. Whether it is caused by an ELST that is too small to be detected by MRI or is produced by some other etiology is still unknown. Audiologic evaluation and MRI should allow early detection and enhance management of hearing loss in these patients.
个别报告提示内淋巴囊肿瘤(ELST)(在普通人群中极为罕见)与冯希佩尔-林道病(VHL)之间可能存在关联。为确定听力损失和ELST是否为VHL的一部分,我们研究了VHL患者中听力损失和ELST的患病率、临床表现及自然病史。
回顾了对374例接受VHL筛查患者的脑磁共振成像(MRI),以查找ELST的证据。有MRI证据提示ELST或有听力损失、耳鸣或眩晕病史的VHL患者接受了额外的放射学和听力学评估。为进一步评估VHL中听力损失和ELST的患病率,在VHL诊所接受筛查的接下来66例患者(49例确诊VHL,17例有VHL风险)接受了MRI和听力学评估。
转诊中心。
研究对象包括374例接受VHL筛查的人、66例连续的VHL患者或有VHL风险的患者、4例有6个ELST的患者以及13例先前报告的患有VHL和颞骨侵袭性肿瘤的患者。
后颅窝磁共振成像和计算机断层扫描(CT)以及听力学评估。
MRI或CT上可见的任何ELST以及与ELST相符的听力损失。
磁共振成像显示,121例VHL患者中有13例(11%)存在15个ELST的证据,但253例无VHL证据的患者中均未发现(P<0.001)。这13例患者的临床表现包括听力损失(13例)、耳鸣(12例)、眩晕(8例)和面瘫(1例)。听力损失开始时的平均年龄为22岁(范围12 - 50岁)。所有受影响耳朵以及另外11只据称未受影响耳朵中的6只耳朵的纯音听力均异常。8例患者(62%)中,听力损失是VHL的首发表现。听力损失的有无与症状持续时间(P<0.002)和肿瘤大小(P<0.01)相关。此外,VHL诊所的66例患者中有43例(65%)存在纯音阈值异常,43例受影响受试者中有23例(54%)双侧出现异常;然而,尚无确凿证据表明与ELST存在关联(49例确诊VHL的患者中有3例[6%]MRI上有明显的ELST)。
听力损失和ELST常与VHL综合征相关,在筛查有VHL风险的个体以及监测已确诊VHL的患者时应予以考虑。许多VHL患者有听力损失,但无MRI证据显示存在ELST。其原因是ELST太小无法被MRI检测到还是由其他病因引起仍不清楚。听力学评估和MRI应有助于早期发现并加强对这些患者听力损失的管理。